Anal cancer
Lynparza tablets for the treatment of Platinum-sensitive relapsed ovarian cancer regardless of BRCA status: approved in European Union
The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for...
European Commission has approved Cabometyx for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma
The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...
Olaparib in combination with Abiraterone delays disease progression in metastatic castration-resistant prostate cancer
Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...
Non-metastatic castration-resistant prostate cancer: Enzalutamide delays metastasis-free survival versus placebo without worsening HRQoL in PROSPER trial
The phase 3 PROSPER trial has showed a statistically significant improvement in metastasis-free survival ( MFS ) with Enzalutamide (...
Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer, approved in European Union
The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...
ADXS-PSA plus Pembrolizumab in metastatic castration-resistant prostate cancer: KEYNOTE-046
ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...
Nivolumab plus Platinum-doublet chemotherapy vs chemotherapy as first-line treatment for advanced non-small cell lung cancer with less than 1% tumor PD-L1 expression: CheckMate 227
CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab...
Nivolumab plus Ipilimumab versus Platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: safety analysis from CheckMate 227
CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy...
Imfinzi is the first immunotherapy for the treatment of locally-advanced, unresectable NSCLC in patients whose tumours express PD-L1 on 1% or more of tumour cells
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...
FDA has approved Lumoxiti for the treatment of hairy cell leukemia
The FDA ( U.S. Food and Drug Administration ) has approved Lumoxiti ( Moxetumomab pasudotox-tdfk ) injection for intravenous use...
Combination therapy based on Tafinlar and Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma: approved in European Union
The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment...
Normal tissue BRCA1 promoter methylation is positively associated with risk for high-grade serous ovarian cancer
The role of normal tissue gene promoter methylation in cancer risk is poorly understood. A study has evaluated associations between normal...
Clonal hematopoiesis may be a modifiable risk factor for atherosclerotic cardiovascular disease
Aging is associated with an increased incidence of cancer and cardiovascular disease. Researchers recently used whole-exome sequencing data to identify...
Breast cancer, drug treatments are often stopped five years after removal of the primary tumour. These women are still at risk of relapse
The main aim of adjuvant therapy, which is given after an apparently successful primary cancer treatment, is to reduce the...
PROSPER trial: Enzalutamide reduces the risk of metastasis or death by 71% in men with non-metastatic castration-resistant prostate cancer
The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...
SPARTAN trial, Apalutamide, an androgen receptor inhibitor, improves median metastasis-free survival by more than two years in patients with non-metastatic castration-resistant prostate cancer
New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...
FDA has approved Erleada, a new treatment for non-metastatic castration-resistant prostate cancer
The FDA ( U.S. Food and Drug Administration ) has approved Erleada ( Apalutamide ) for the treatment of patients...
Revlimid as monotherapy for the maintenance treatment of patients with newly diagnosed multiple myeloma after autologous stem cell transplantation, approved in European Union
The European Commission ( EC ) has approved Revlimid ( Lenalidomide ) as monotherapy for the maintenance treatment of adult...
Carfilzomib significantly improves overall survival compared to Bortezomib in relapsed or refractory multiple myeloma patients
Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were...
Kisqali approved by FDA in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with HR–positive, HER2-negative advanced breast cancer
The CDK 4/6 inhibitor Ribociclib ( Kisqali ) has been approved by the FDA ( Food and Drug Administration )...